GENEART and MorphoSys Successfully Cooperate in HuCAL PLATINUM Project
"In GENEART we found the right partner in the field of DNA Engineering and Directed Evolution for this complex project. The high quality of the gene libraries produced and GENEART's sequence optimization were essential requirements for the realization of HuCAL PLATINUM®'s increased diversity and improved expression rates", explained Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
"The MorphoSys technology has already set a standard for the development of therapeutic antibodies in the past. All the more we are pleased to have made a contribution to the further development of this powerful tool. In addition, our cooperation is a good example of how GENEART adds definite value for the customer by combining proprietary optimization technology with our knowhow in the field of Directed Evolution", commented Prof. Dr. Ralf Wagner, CEO of GENEART AG.
Other news from the department business & finance
These products might interest you
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous